- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01460095
Improving Access to HbA1c in Sub Saharan Africa (IA3)
Improving Access to HbA1c Measurement in Sub-Saharan Africa
Studieoversikt
Detaljert beskrivelse
The objective is to determine whether the introduction of routine affordable HbA1c determination with immediate feedback to patients and relevant education in an underserved population without any further intervention on drug supply would significantly improve diabetes control. As this will be an after-versus-before type study, each patient will be his own control.
Study setting The study will be undertaken in 10 existing diabetes care centre in two countries, including 4 regional centers in Guinea, a West African country of 10 millions inhabitants, and 6 regional centers in Cameroon, a Central African country of 18 million inhabitants.
The health districts covered in Guinea are Conakry, Labe, Kankan and Boke each being situated in a different ecological and cultural areas. In Cameroon, the health districts covered are Biyem Assi in Yaoundé, Garoua, Limbe, Ebolowa, Bamenda, Bafoussam also covering the 4 ecological zone of Cameroon.
All these health districts have existing diabetes care centre with trained personnel run in public hospital with prices and medicine affordable to most of the population covered. However, none of these centers have an HbA1c machine, and diabetes control is mainly evaluated using blood glucose, most often fasting.
Target population The aim is to provide the service to all patients followed in the selected centers at low cost however the first eligible 1000 patients will be included in the formal intervention free of charge.
Eligibility All patients with a physician-confirmed diagnosis of diabetes and who have been followed in the diabetes centre for at least one year are eligible Sample size In order to detect a difference of 1 unit (1% glycated haemoglobin) between to samples with a standard deviation of 1.2%, alpha coefficient of 0.001 and 0.8 power using a two-sided test, a minimum population of 80 subjects is required. The minimum sample size if alpha is 0.01 is 55 subjects. We therefore decided a sample size of 100 patients per centre in order to be able to analyze data taking into account center or physician effect. It thus give an overall sample size of 1000 subjects.
Sampling method We will use a systematic sampling, enrolling consecutive eligible patients volunteering to participate until completion of the sample size in each individual centre.
Inclusion All eligible patients, not intending to migrate from the study site within 1 year, and volunteering to participate will be enrolled. At inclusion the following will record of demographic characteristics, past medical history, characteristics of diabetes, evaluation of patient knowledge, and measurement of anthropometric characteristics, blood pressure, haematocrit, HbA1c, and urinary albumin excretion at baseline.
Intervention and follow up:
Data will be collected using a clinical record form designated to this effect. The intervention will consist of the measurement of HbA1c at baseline, 3, and 6 months with immediate feedback to patients and provision of targeted education after each determination, on level, significance, and targets.
Treatment will follow usual guidelines with no additional intervention. Adjustment of treatment will be done by the health care personnel in a treat-to-target fashion. No change in drug supply will be introduced. No specific recommendation will be given concerning the frequency of hospital visit between the study visits at baseline, month 3, 6, and 12. Each centre will continue with usual follow up frequency.
At month 12, we will repeat the evaluation of patient knowledge, and the measurement of anthropometric characteristics, blood pressure, haematocrit, HbA1c, and urinary albumin excretion for comparison to baseline.
Timeframe
- Start date: Month 7
- End of enrollment: Month 12
- End of follow-up of last patient enrolled: Month 24
Outcome measures
Primary outcome: Change in HbA1c from baseline to 12 months
Secondary outcomes:
- Change in percentage of patients at HbA1c target from baseline to 12 months
- Change in urinary albumin excretion from baseline to 12 months The other measures will serve for the interpretation of data Deliverables
- Dataset for each centre between Month 24 and Month 26
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Boke, Guinea
- Boke Regional Hospital
-
Conakry, Guinea
- CHU Donka
-
Kankan, Guinea
- Kankan Regional Hospital
-
Labe, Guinea
- Labe regional Hospital
-
-
-
-
-
Bafoussam, Kamerun
- Bafoussam District Hospital
-
-
Centre
-
Yaounde, Centre, Kamerun
- Yaoundé Central Hospital
-
-
North
-
Garoua, North, Kamerun
- Garoua Regional Hospital
-
-
North West
-
Bamenda, North West, Kamerun
- Bamenda Regional Hospital
-
-
South West
-
Buea, South West, Kamerun
- Buea Regional Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Confirmed diabetes mellitus irrespective of type
- Patients who have been followed regularly for at least one year prior to inclusion in the target health facilities
- Adult age (18 years and over)
Exclusion Criteria:
- Individuals planning to migrate from study sites within one year
- Any intercurrent acute illness
- Enrollment in any other concomitant intervention study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: HbA1c measurement and education
3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
|
three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
one year change in glycated haemoglobin (HbA1c)
Tidsramme: Baseline and 12 months
|
Baseline to 12 months individual change in HbA1c level
|
Baseline and 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
One-year change in proportion of patients reaching HbA1c targets
Tidsramme: Baseline and 12 months
|
Baseline to 12 months change in proportion of patients reaching HbA1c targets in each participating centre and in the overall population
|
Baseline and 12 months
|
One-year change in urinary albumin excretion
Tidsramme: Baseline and 12 months
|
Baseline to 12 months individual change in early morning sample urinary albumin excretion
|
Baseline and 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Eugene Sobngwi, MD, PhD, Newcastle University, UK and Yaounde Central Hospital, Cameroon
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- LT07-135 (International Diabetes Federation)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sukkersyke
-
Medical College of WisconsinMedical University of South CarolinaFullførtSukkersyke | Type 2 diabetes mellitus | Voksendiabetes mellitus | Ikke-insulinavhengig diabetes mellitus | Ikke-insulinavhengig diabetes mellitus, type IIForente stater
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.FullførtDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinavhengig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinavhengig diabetes mellitus 1 | Diabetes mellitus, insulinavhengig, 1 | Diabetes mellitus, sprø | Diabetes mellitus... og andre forholdForente stater
-
SanofiFullførtType 1 Diabetes Mellitus-Type 2 Diabetes MellitusUngarn, Den russiske føderasjonen, Tyskland, Polen, Japan, Forente stater, Finland
-
Meir Medical CenterFullførtDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, om oral hypoglykemisk behandling | Voksen type diabetes mellitusIsrael
-
Peking Union Medical College HospitalUkjentType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskapsdiabetes mellitus | Pankreatogen diabetes mellitus | Pregestasjonell diabetes mellitus | Diabetespasienter i perioperativ periodeKina
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pankreatogen diabetes | Legemiddelindusert diabetes mellitus | Andre former for diabetes mellitusKina
-
Hoffmann-La RocheRoche DiagnosticsFullførtDiabetes mellitus type 2, diabetes mellitus type 1Tyskland
-
University of California, San FranciscoJuvenile Diabetes Research FoundationFullførtType 1 diabetes mellitus | Diabetes mellitus, type I | Insulinavhengig diabetes mellitus 1 | Diabetes mellitus, insulinavhengig, 1 | IDDMForente stater, Australia
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and...Aktiv, ikke rekrutterendeDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, ikke-insulinavhengigForente stater
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, ikke-insulinavhengigForente stater
Kliniske studier på HbA1c measurement and education
-
University of ArkansasNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Rekruttering
-
Abant Izzet Baysal UniversityHar ikke rekruttert ennåType 1 diabetes | Pediatrisk sykepleie
-
University of ArkansasNational Institute on Minority Health and Health Disparities (NIMHD)RekrutteringType 2 diabetesForente stater
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Fullført
-
University of OxfordBeijing Normal University; Beijing Stars and Rain Education Institute for...FullførtBarnemishandling | Foreldre-barn forhold | Autismespektrumforstyrrelse | Foreldre | Barns atferdsproblem | Familieforhold | Psykisk helseproblemKina
-
Omada Health, Inc.Palo Alto Medical Foundation; Sutter HealthAvsluttetType 2 diabetesForente stater
-
WestatChildren's Bureau - Administration for Children and Families; Illinois...Fullført
-
National Taiwan University Hospital Hsin-Chu BranchNational Taipei University of Nursing and Health SciencesRekrutteringSår | TrykkskadeTaiwan
-
NYU Langone HealthAgency for Healthcare Research and Quality (AHRQ)Har ikke rekruttert ennåType 2 diabetesForente stater
-
University of ArizonaRekruttering